



**Investor briefing:
Major Development and IP Agreements with leading
global women's health company, Hologic, Inc.**

16 January 2024

For personal use only

Disclaimer and Important Information



This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Non-IFRS financial measures

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

Company snapshot



Lumos is a developer and manufacturer of connected instrumentation and rapid point-of-care tests for the diagnostics and healthcare industries

- Led by Doug Ward, industry veteran with over 30 years' experience in diagnostics
- Comprehensive offering from concept design, to clinical, to commercial production
- Proprietary reader platforms providing connected use in different clinical settings
- Development and manufacturing facility located in Carlsbad, California

• Strategic relationship with US-based women's health leader Hologic – expanded in January 2024 with two transformative new agreements

- Two POC tests, FebriDx and ViraDx cleared in certain markets available for commercial sale or licensing
- Distributor of other women's health and sexual health products




For personal use only

Lumos' POC diagnostic test development engine



For personal use only



REVENUE
STREAMS

Contract Fees
from services

Revenue & Margin
from manufacturing

Sales & License Payments
from own & other products



Strategic partnership with Hologic



- **Hologic is a recognized global leader in women's health based in Massachusetts, US**
 - NASDAQ: HOLX, Market Capitalization ~US\$18 billion
 - FY2023 revenue of US\$4.0 billion with net income of US\$0.5 billion
 - Diagnostic products account for ~50% of Hologic's revenue
- **Historic relationship with Lumos <> Hologic – working together at multiple levels**
 - Multiple services contracts signed during FY2023
 - Existing, marketed product
 - Development of a new, rapid point-of-care test product
 - US\$4.2 million in non-dilutive funding through sale and leaseback agreement



New Major Development and IP Agreements with Hologic



The new Agreements build on work conducted by Lumos and Hologic over the last 12+ months and focus on the development of an improved version of one of Hologic's leading on market women's health products, including adapting it for use on Lumos' proprietary reader platform.

- The two new agreements are for the development of, and intellectual property rights for, custom reader and point of care technologies.
- The IP Agreement provides Hologic with an exclusive license in the field of fetal fibronectin to Lumos' proprietary reader and POC technologies that will be incorporated into the next generation product, under development.
- IP Agreement is valued at US\$10M in two non-refundable payments:
 - US\$5.0M upon signing
 - US\$5.0M in June 2024
- Development Agreement valued at up to US\$4.7M in payments over an 18-24 month period, dependent on the achievement of specified milestones.
- Development Agreement has been broken down into three phases:
 - 1) Product Definition and Planning - define the parameters for the product and establish a project plan US\$0.4 million;
 - 2) Assay Feasibility - conduct work to demonstrate the assay is able to detect the biomarkers US\$0.6 million; and
 - 3) System Prototype Delivery – deliver a working prototype of the system - US\$3.7 million providing total milestone payments of up to US\$4.7 million.
- ASX announcements from 11 and 16 January 2024 provide additional information.

These new contracts strengthen Lumos' balance sheet and provide a pipeline of revenue generating partnerships in POC diagnostics.

For personal use only

Questions

For personal use only



LUMOS
DIAGNOSTICS

www.lumosdiagnostics.com